# OnCo record rtog-0521 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rtog-0521/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rtog-0521", "NCT00288080" ;
  schema:name "NRG Oncology RTOG 0521"@en ;
  schema:alternateName "RTOG 0521"@en, "NRG/RTOG 0521"@en ;
  schema:description "Adding chemotherapy to hormone therapy and radiotherapy for the most aggressive localised prostate cancer improved four-year survival from 89 to 93 percent."@en ;
  schema:url <https://onco.cc/trials/rtog-0521/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00288080>, <https://doi.org/10.1200/JCO.18.02158> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/nrg-oncology/> ;
  onco:terms <https://onco.cc/terms/adt/>, <https://onco.cc/terms/curative-intent/>, <https://onco.cc/terms/gleason-grade-group/> ;
  onco:trials <https://onco.cc/trials/stampede/>, <https://onco.cc/trials/chaarted/> .